SEATTLE, May 21, 2010 -- KING Television (Channel 5; NBC) aired a story May 20 about the Alair® Bronchial Thermoplasty System, which the U.S. Food and Drug Administration (FDA) approved April 27, 2010 for the treatment of severe, persistent asthma in patients 18 years and older whose asthma is not well controlled with inhaled corticosteroids and long-acting beta agonists -- the current standard-of care treatment for these patients.
Bronchial thermoplasty, which is the first device-based asthma treatment approved by the FDA, is a novel outpatient procedure developed by California-based Asthmatx. It delivers precisely controlled thermal energy to reduce excess airway smooth muscle that is associated with airway constriction in patients with asthma. By decreasing the ability of the airways to constrict, this new treatment has been shown to help patients with severe asthma gain substantially better control over their disease.
FDA approval of the Alair System was largely based on the promising results of the AIR2 Trial, a double-blind, randomized study that Swedish took part in and which was designed to evaluate the safety and effectiveness of bronchial thermoplasty in adult patients with severe asthma. The study results were published in the Jan. 15, 2010 issue of the American Journal of Respiratory and Critical Care Medicine.
As a result of the medical center's involvement in the AIR2 Trial, Swedish is the only provider in the Pacific Northwest currently offering this procedure.
To watch this story and/or read the transcript on the KING 5 TV Web site, click here.
To watch a related story on WebMD.com, click here.
For more information about this procedure and its availability, call Swedish Thoracic Surgery at 206-215-6800 or visit www.swedishthoracicsurgery.org.